- Details
- Zachary Klaassen reviews a JAMA Oncology publication entitled, "Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening." This large national cohort study found that rates of PSA testing increased after the USPSTF's draft statement in 2017, reversing trends seen after earlier guidance against PSA testing for...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication “Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.” This retrospective cohort study aims to assess the contemporary practice patterns regarding the use of dual-energy x-ray absorptiometry...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen discusses a review paper entitled "Mechanisms Mitigation and Management of Urinary Toxicity from Prostate Radiotherapy." The review discusses the prevalence and difficulty of managing urinary toxicity in patients receiving pelvic radiotherapy, especially those with prostate cancer, and the importance of long-term survivorship and reducing tre...
|
- Details
- Chris Wallace and Zach Klaassen discuss updates in the 2023 NCCN Clinical Practice Guidelines in Oncology for prostate cancer. They focus on a new section of the guidelines that emphasize the importance of shared decision-making and maintaining quality of life during prostate cancer treatment. As part of the guidelines, the panel recommends baseline measures of disease-specific functions, includin...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication entitled Prostate Cancer Screening Using Combination of Risk Prediction, MRI, and Targeted Prostate Biopsies, the STHLM3-MRI trial. The study performed a prospective, randomized, population-based trial among men aged 50 to 74 to evaluate various prostate cancer screening strategies. The study showed that replacing PSA with S...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen discusses the publication "Polygenic Risk of Any, Metastatic, and Fatal Prostate Cancer in the Million Veteran Program." The publication explores the potential use of genetic risk scores in identifying individuals most at risk of developing advanced prostate cancer, particularly those who may benefit most from PSA testing and screening. The p...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen discusses the publication "Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial." The study evaluates the effectiveness of a hyaluronic acid rectal spacer in reducing the risk of acute gastrointestinal toxicity in patients undergoing hypofractionated radiation therapy for prostate cancer. The stu...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen discusses the publication "Magnetic Resonance Imaging-Guided Versus CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial." This study compared CT-guided and MRI-guided SBRT for localized prostate cancer. Results showed that the aggressive margin reduction afforded by MRI guidance allowed a substan...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen discusses the publication "Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden." The study aims to investigate the long-term outcomes following active surveillance for prostate cancer using a state transition model. Data from the Swedish prostate cancer database included men aged 40 to 75 years diagnosed...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen analyzes the Journal of Clinical Oncology publication, "Darolutamide Plus ADT and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial." The ARASENS trial, a multicenter, randomized, double-blind, placebo-controlled Phase III study across 23 countries, assesses the combi...
|
